Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Clinical trial NCT04936295 · UNKNOWN
Trial details
- NCT number
- NCT04936295
- Sponsor
- Sun Yat-sen University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-16
- Primary completion
- 2023-06-01
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.